Reliable temperature-controlled coronavirus vaccine logistics require smooth integration of all those involved as well as materials that provide good insulation. As the range of coronavirus vaccines grows, so do the requirements for their distribution. The different vaccines need to be stored and transported at different temperature ranges – often together in the same vehicle or cold store. Handling complex processes like this is routine for leading logistics companies. But they depend on the skills of packaging providers and raw materials suppliers.
Logistics companies were already transporting pharmaceutical products at minus 70°C in boxes packed with dry ice before the coronavirus pandemic. Many of these methods are not new. The challenge for the coronavirus vaccine logistics in relation to the cooling systems is rather to adapt the known technology as quickly as possible to specific requirements such as pack sizes as well as storage and transport times.
Developed recently are passive – in other words non-electric cooling systems for the pharmaceutical industry. The lightweight thermal boxes can be fitted with special cooling elements for almost any temperature range and for different volumes. This flexibility in terms of size and cooling range comes into play with the coronavirus vaccine logistics, as three very different temperature ranges – minus 70°C, minus 15°C to minus 25°C, and plus 2°C to plus 8°C- need to be ensured.
However, there is a misconception that a higher temperature means lesser effort. The minus 15°C to minus 25°C range may place higher demands on the packaging than minus 70°C.
Dry ice, with its temperature of minus 78°C, cannot be used in this situation, where special cooling elements are required instead. These elements need to be cold but not too cold, so the temperature does not fall below minus 25°C but enough cooling energy still ends up in the box.
The process is invariably sophisticated in that it needs to run smoothly from the vaccine manufacturer via the packaging producer and logistics company all the way to the user of the individual vaccine doses. Before it was practically employed, the on-purpose-developed cooling systems have already successfully undergone a demanding qualification process. They have been exposed to changing ambient temperatures in the pilot climate chambers. This ensures that the defined temperature limits are reliably maintained.
The raw materials for the pharmaceutical boxes are extremely important and need to have very good insulating properties. They are made up of expandable polystyrene (EPS) granules custom-made for the purpose. So far, logistics service providers have already delivered tens of thousands of vaccine doses at the correct temperature in the custom-made EPS boxes. Hundreds of thousands will follow.
The United States has been pushing India to restart vaccine exports as it looks to stem the global spread of the Covid pandemic.
Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.
The shippers are in for struggle yet another time, with the market buzzing in speculations of liners planning of ‘blank sailing’ during China’s Golden Week holiday in early October to extract maximised profits.
Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country’s high infection and severe illness rates fuelled by the fast-spreading delta variant, officials and scientists say.
Researchers have developed a blood test able to detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.
At Last: Separated and Freshly Bound –
Amidation of light alkanes
AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.
Interruptions to the inspection programme of the European Directorate for the Quality of Medicines & HealthCare (EDQM) due to travel restrictions – made necessary by the COVID-19 pandemic – led to the creation of a system of Real-Time Remote Inspections (RTEMIS).